T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company's participation in two conferences in February: Society of Critical Care Medicine's (SCCM) 48th Critical Care Congress, and Medlab Middle East 19th Annual Laboratory Management and Medicine Conference.
"A recent study in The Lancet estimated that 11 million people died with sepsis in 2017 -- accounting for nearly 20% of all deaths worldwide -- more deaths than all forms of cancer combined," said John Sperzel, Chief Executive Officer of T2 Biosystems. "We are excited to further demonstrate how our technology is helping to improve clinical outcomes and make a meaningful difference in the lives of patients suspected of sepsis."
At the Medlab Middle East congress in Dubai, held February 3-6, 2020, Professor Pavel Drevinek, M.D., Ph.D. from Motol University Hospital in the Czech Republic will present, "Using T2MR Technology for rapid detection of ESKAPE Pathogens directly from whole blood." The presentation will highlight the real-world, positive impact that T2 Biosystems' rapid diagnostics that detect sepsis-causing pathogens can have on patients and clinicians.
During the SCCM's Congress, held in Orlando, Florida, on February 16-19, 2020, the Company, including T2 Biosystems' Vice President of Medical Affairs, Sandy Estrada, Pharm. D., will highlight the capabilities of its T2Bacteria(R) and T2Candida(R) panels. These panels are the only FDA cleared diagnostic tools that can detect sepsis-causing pathogens in the bloodstream directly from whole blood, providing results in three to five hours instead of days, as is seen with current blood culture-based methods. As a result, patients can receive targeted treatment sooner, and hospitals can better manage costs associated with identifying and treating sepsis, including antimicrobial costs.
Attendees can learn more about the Company's innovations, as well as their clinical and economic benefits, at SCCM at Booth #1123.
About T2 Biosystems
T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in health care, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx(R) Instrument, the T2Candida(R) Panel, the T2Bacteria(R) Panel, and the T2Resistance Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR(R)) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding additional patients, timing of testing patients, anticipated product benefits, strategic priorities, product expansion or opportunities, growth expectations or targets, timing of FDA filings or clearances and anticipated operating expenses, as well as statements that include the words "expect," "intend," "plan", "believe", "project", "forecast", "estimate," "may," "should," "anticipate," and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, on March 14, 2019, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.
Gina Kent, Vault Communications
Zack Kubow, W2O Group